caa a22 4500 44533455X CHVBK 20180317142750.0 cr unu---uuuuu 170323e20111101xx s 000 0 eng 10.1245/s10434-011-1723-2 doi (NATIONALLICENCE)springer-10.1245/s10434-011-1723-2 Rates of Venous Thromboembolism Among Patients with Major Surgery for Cancer [Elektronische Daten] [Jeffrey Hammond, Chris Kozma, James Hart, Somesh Nigam, Mehmet Daskiran, Andrew Paris, John Mackowiak] Background: Previous studies have reported VTE rates during surgical stays in hospitals or by diagnoses over extended periods without being linked to specific surgical events. The purpose of this project was to assess the potential rate of venous thromboembolism in patients with cancer after a surgical procedure within the immediate posthospital admission period of 30days, with special emphasis in increased sensitivity of detection. Methods: Patients with cancer who had a major surgery were identified in a large commercial (non-Medicare) database containing data from more than 22 million patients in the United States. Those with a new diagnosis of VTE within 30days postadmission for surgery were identified. Additional drug-based criteria were used to vary the VTE definition in a sensitivity analysis. VTE rates are reported for each of the surgical procedure group and overall. Results: The overall 30-day VTE rate was 3.5% with a diagnosis based definition, with rates ranging by procedure from 1.8 to 13.2%. Esophageal resection patients have a VTE rate of 13.2% (95% confidence interval (CI), 8.8-18.9%), whereas prostatectomy patients have a VTE rate of 1.8% (95% CI, 1.5-2.1%). Of the 3.5% of patients with a VTE diagnosis on or before postoperative day 30, 73% of those have the VTE diagnosis by day 14. Another 1.15% is added to the overall VTE rate as the definition sensitivity is increased with outpatient pharmacy claims data. Conclusions: Using administrative data from large populations provides valuable insight into the potential VTE rates that occur within the 30-day post period after various cancer-related surgeries. The information can be used by surgeons as one component of the benefit-risk decision regarding postoperative VTE prophylaxis in surgical patients. Society of Surgical Oncology, 2011 Hammond Jeffrey Ethicon Biosurgery, Ethicon, Inc, Somerville, NJ, USA aut Kozma Chris CK Consulting, Steamboat Springs, CO, USA aut Hart James Ethicon, Inc, Somerville, NJ, USA aut Nigam Somesh Johnson & Johnson, New Brunswick, NJ, USA aut Daskiran Mehmet Johnson & Johnson, New Brunswick, NJ, USA aut Paris Andrew Vigilytics, Victor, NY, USA aut Mackowiak John Center for Outcomes Research, Nashville, TN, USA aut Annals of Surgical Oncology Springer-Verlag 18/12(2011-11-01), 3240-3247 1068-9265 18:12<3240 2011 18 10434 https://doi.org/10.1245/s10434-011-1723-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-011-1723-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Hammond Jeffrey Ethicon Biosurgery, Ethicon, Inc, Somerville, NJ, USA aut NATIONALLICENCE 700 1- Kozma Chris CK Consulting, Steamboat Springs, CO, USA aut NATIONALLICENCE 700 1- Hart James Ethicon, Inc, Somerville, NJ, USA aut NATIONALLICENCE 700 1- Nigam Somesh Johnson & Johnson, New Brunswick, NJ, USA aut NATIONALLICENCE 700 1- Daskiran Mehmet Johnson & Johnson, New Brunswick, NJ, USA aut NATIONALLICENCE 700 1- Paris Andrew Vigilytics, Victor, NY, USA aut NATIONALLICENCE 700 1- Mackowiak John Center for Outcomes Research, Nashville, TN, USA aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/12(2011-11-01), 3240-3247 1068-9265 18:12<3240 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer